HelpAcademyLoginJoin us as a Member

Sarepta Therapeutics, Inc.

Sign in to save Sarepta Therapeutics, Inc. to a watchlist Sign in to set an alert for Sarepta Therapeutics, Inc.
Tickers
SRPT
Headquarters
Not recorded
SEC CIK
0000873303
Website
Not recorded

Closing prices

Drugs

Drugs from Sarepta Therapeutics, Inc.
DrugIndicationsPhaseNext catalystCT-VCATrials
SRP-4045Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save SRP-4045 to a watchlist Duchenne Muscular DystrophyPhase 3None scheduledNo published CT-VCA score1
SRP-4053Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save SRP-4053 to a watchlist Duchenne Muscular DystrophyPhase 3None scheduledNo published CT-VCA score1
SRP-9003Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save SRP-9003 to a watchlist Limb-girdle Muscular DystrophyPhase 3None scheduledNo published CT-VCA score1

FDA-approved applications

Catalysts

No catalysts yet. Editors add each date together with its source.

Deals

No approved deals involve this company yet.

Reported fundamentals (SEC XBRL)

SEC filings

SEC filings from Sarepta Therapeutics, Inc., newest first
FormFiledWhat it coversDocument
4Event 4 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 8 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-385545 (opens in a new tab)
4Event 4 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 8 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-385544 (opens in a new tab)
4Event 4 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 8 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-385541 (opens in a new tab)
4Event 4 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 8 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-385536 (opens in a new tab)
8-K Current report (8-K)
  • Results of operations and financial condition (Item 2.02)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 5 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-335056 (opens in a new tab)
10-QEvent 30 Jun 2026 Quarterly report (10-Q) View Quarterly report (10-Q) filed 5 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-335003 (opens in a new tab)
4Event 28 Jul 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 29 Jul 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-324445 (opens in a new tab)
8-KEvent 23 Jul 2026 Current report (8-K)
  • Departure or appointment of directors or officers (Item 5.02)
  • Regulation FD disclosure (Item 7.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 27 Jul 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-316995 (opens in a new tab)
4Event 4 Jun 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 5 Jun 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-260263 (opens in a new tab)
4Event 4 Jun 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 5 Jun 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-260261 (opens in a new tab)

Source: SEC EDGAR. Each row links to the filing on sec.gov.

Related news

No recent headlines mention this company.

Insider transactions

All rows for Sarepta Therapeutics, Inc. on Insider Trades

Last 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).

Buys code P
None in this period
Sells code S
None in this period
Other all other codes
4 transactions: grants, exercises, tax withholding, gifts and similar

Last transaction:

Insider filings are public records and are not a recommendation. Source: SEC EDGAR.

Sources

Nothing on this page is investment advice.